04.04.13
Aragen Bioscience and Innovent Biologics have entered a collaboration for the development and manufacture of cell lines for biotherapeutic product development. Aragen Bioscience will develop CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics.
“Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products,” said Michael Yu, chief executive officer of Innovent.
“Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration,” said Oren Beske, Ph.D., vice president of Aragen Bioscience.
“Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products,” said Michael Yu, chief executive officer of Innovent.
“Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration,” said Oren Beske, Ph.D., vice president of Aragen Bioscience.